A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is trying to see if a new medicine called talquetamab works better than an old medicine called belantamab mafodotin. They will be looking at how many people respond well to the medicine overall or how long people can go without their cancer getting worse.
This study is trying to see if a new medicine called talquetamab works better than an old medicine called belantamab mafodotin. They will be looking at how many people respond well to the medicine overall or how long people can go without their cancer getting worse.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).
The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.